// AST – IMS - [DMinute_ROS]

Finance News

Theravance Biopharma’s (TBPH) “Strong-Buy” Rating Reaffirmed at Zacks Investment Research

Zacks Investment Research reaffirmed their strong-buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note issued to investors on Friday morning. They currently have a $29.00 target price on the biopharmaceutical company’s stock.

Goldman Sachs Group Upgrades Puma Biotechnology (PBYI) to Neutral

Puma Biotechnology (NASDAQ:PBYI) was upgraded by equities research analysts at Goldman Sachs Group from a “sell” rating to a “neutral” rating in a research report issued to clients and investors on Monday, The Fly reports.

Insider Selling: G1 Therapeutics Inc (GTHX) Insider Sells $150,096.00 in Stock

G1 Therapeutics Inc (NASDAQ:GTHX) insider Rajesh Malik sold 3,776 shares of the company’s stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $39.75, for a total value of $150,096.00. The transaction was disclosed in a document filed with the SEC, which […]

Celgene Co. (CELG) Shares Bought by HCR Wealth Advisors

HCR Wealth Advisors lifted its position in Celgene Co. (NASDAQ:CELG) by 7.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,949 shares of the biopharmaceutical company’s stock after purchasing an additional 824 shares during the […]

HCR Wealth Advisors Acquires 1,081 Shares of Charles Schwab Co. (SCHW)

HCR Wealth Advisors increased its holdings in Charles Schwab Co. (NYSE:SCHW) by 2.9% in the third quarter, HoldingsChannel reports. The firm owned 38,224 shares of the financial services provider’s stock after purchasing an additional 1,081 shares during the period. HCR Wealth Advisors’ holdings in Charles Schwab were worth $1,730,000 as of its […]

Comparing Viaspace (VSPC) and ARC Document Solutions (ARC)

Viaspace (OTCMKTS:VSPC) and ARC Document Solutions (NYSE:ARC) are both small-cap industrial products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.